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Pulmonary Hypertension (PH) is defined as an 
increase in mean pulmonary arterial pressure (PAP) ≥25 
mmHg at rest as assessed by right heart catheterization 
(RHC). As stated in the European Society of Cardiology 
(ESC) 2009 guidelines, it can be classified into 5 main 
categories, presented in Table 1. Pulmonary arterial 
hypertension is a rare disease with a prevalence of 15 
cases /million adult population and an incidence of 2.4 
cases/million adult population/year.1,2 The 
pathophysiology of PH is complex and it has not been 
elucidated in detail since it involves various biochemical 
pathways and cell types. Vasoconstriction, remodeling 
with extensive proliferation of the vessel wall cells 
causing progressive obstruction, inflammation and 
thrombosis have been implicated. Structural or functional 
abnormalities of potassium channels in the smooth 
muscle cells and endothelial dysfunction characterized by 
impaired nitric oxide (NO) and prostacyclin production or 
increased expression of thromboxane A2 and endothelin-
1are thought to underlie the cellular changes.3  
Although groups two and three account for the 
majority of the cases, the trials testing and validating 
therapeutic options involve mostly patients with group 
one PH (Pulmonary Arterial Hypertension-PAH). Apart 
from conventional therapy including diuretics, oral 
anticoagulants, calcium channel blockers in case of 
established vasoreactivity, digoxin, oxygen 
administration and exercise –rehabilitation programs, 
specific drugs have emerged and gradually find their 
place in the management of PAH during the last decade. 
Prostanoids such as intravenous (IV) epoprostenol, 
iloprost inhaled and IV and treprostinil subcutaneously 
(SC) or IV have been established agents in the 
management of PAH, improving performance ability and 
survival (epoprostenol). Beraprost has shown promising 
albeit short –term results in the ALPHABET trial.4-10 
Phosphodiesterase (PDE) type-5 inhibitors (sildenafil, 
tadalafil) and endothelin receptor antagonists (bosentan, 
ambrisentan) improve exercise capacity and 
hemodynamic parameters and are widely used in the 
treatment of PAH.11-16 Sitaxentan demonstrated 
favourable results initially 17, 18 but was subsequently 
withdrawn in early 2011 due to a few cases of fatal 
hepatic toxicity considered to be idiosyncratic, 
unpredictable and thus unpreventable. 
 
Table 1. Classification of Pulmonary Hypertension  
 
Pulmonary Arterial 
Hypertension (PAH) 
PH due to Lung Diseases 
&/or Hypoxia 
Idiopathic (IPAH) Chronic obstructive pulmonary 
disease (COPD)
Heritable/familial (FPAH) Interstitial lung disease
       BMPR2       ALK1, Endoglin 
       Unknown
Other pulmonary diseases with 
mixed restrictive & obstructive 
pattern 
Drug and toxin-induced Sleep disordered breathing
Associated with APAH Alveolar hyperventilation dis.
       Connective tissue disorders  Chronic exposure of high 
altitude 
       HIV infection Developmental abnormalities
       Portal hypertension  
       Congenital heart diseases Chronic Thromboembolic PH 
(CTEPH) 
       Schistosomiasis  
       Chronic hemolytic anemia PH with Indistinct, Multi-
factorial Mechanisms
Persistent PH of the newborn 
(PPHN)
Hematological dis. (e.g. myelo-
proliferative dis., splenectomy, 
hemoglobinopathies)  
Pulmonary Veno-Occlusive 
Disease (PVOD) & 
Pulmonary Capillary 
Systemic dis. (e.g. sarcoidosis, 
pulmonary Langerhans cell 
histocytosis, lymphangiomatosis) 
Metabolic dis. (e.g. glycogen 
storage disease, Gaucher’s 
disease, thyroid disorders) 
PH with Left Heart Disease 
Systolic dysfunction 
Diastolic dysfunction Others (e.g. tumoural 
obstruction, fibrosing 
mediastinitis, chronic renal 
failure & dialysis)
Valvular disease
 
ALK-1 = activin receptor-like kinase 1 gene; APAH = associated 
pulmonary arterial hypertension; BMPR2 = bone 
morphogenetic protein receptor, type 2; dis. = disorders; HIV = 
human immunodeficiency virus; PAH = pulmonary arterial 
hypertension; PH = pulmonary hypertension 
  
In spite of the remarkable progress in the management 
of PAH, the response cannot yet be characterized 
satisfactory. Moreover, the cost of specific treatment is 
still considerably high. Thus, the need for novel medical 
approaches is still present. New agents of the already 
used categories are tested. Macitentan, a novel endothelin 
(ET)-A/ET-B receptor antagonist, is being evaluated in 
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the SERAPHIN trial, after producing a promising 
hemodynamic profile in a previous phase II study. 19,20  
The signaling pathways of cyclic (c) GMP play a 
cardinal role in the pathogenesis of PAH. cGMP levels 
are decreased in the pulmonary vascular bed either 
through impairment of NO bioavailability, guanylyl 
cyclase inactivation or enhanced cGMP degradation by 
PDEs.21,22 Consequently, augmentation of cGMP 
signaling is a pathophysiologically reasonable therapeutic 
target. PDE-5 inhibitors are currently a useful option, but 
their effects on pulmonary artery pressure (PAP) are 
small (approximately 5 mmHg reduction), a significant 
number of patients do not respond well and there is often 
a dose-dependent systemic hypotensive effect that limits 
the drug’s utility. Novel attempts focus on NO 
enhancement. NONOates, stable NO donor forms, which 
spontaneously release defined amounts of NO when 
exposed to physiological pH are tested as inhaled 
preparations  with promising results though in animal 
models so far.23,24   
Another way to increase cGMP signaling is by 
enhancing endothelial NO synthase (eNOS). 
Tetrahydrobiopterin (BH4), a key co-factor of eNOS, is 
frequently reduced in patients with PAH and its 
supplementation may increase the enzyme’s activity. 25 
Moreover, cicletanine, an ‘eNOS coupling agent’ has 
beneficial effects in patients with secondary PH. 26 This 
agent probably acts by coordinating eNOS activity with 
BH4 supply/binding, while it may also enhance the 
endogenous formation of prostaglandin (PG) I2 and 
natriuretic peptides. Cicletanine is currently under phase 
II evaluation in patients with PAH. Finally, the 
Pulmonary Hypertension and Cell Therapy trial aims at 
testing the safety and tolerability of autologous progenitor 
cell-based gene delivery of human eNOS in PAH 
patients, since endothelial progenitor cells are thought to 
play a role in the pathogenesis of the disease 27 and it is 
currently recruiting participants. 
Furthermore, soluble Guanyl-cyclase (sGC) agonists 
have been recently developed, which stimulate sGC, both 
independently of the endogenous vasodilator NO and in 
synergy with NO. 28,29 Riociguat is a sGC stimulator or 
haem-dependent activator which works in synergy with 
NO and activates Fe2+-sGC complex. Cinaciguat and 
ataciguat activate the haem-free form of the enzyme and 
act additively with NO. 30,31 The sGC stimulators enhance 
the action of NO and therefore their effect may lack 
pulmonary selectivity, a characteristic which may not be 
the case when the NO independent activators are used. 
However, all agents have been evaluated in phase II trials 
32 and are currently undergoing further testing in various 
clinical settings in relation with PH. 33,34,35 Unfortunately, 
cinaciguat although exhibiting promising results in cases 
of PH due to left-sided heart failure, when given in 
patients with decompensated heart failure, it did not 
improve their clinical condition and was also held 
responsible for episodes of significant hypotension. 33,35 
Novel therapeutic targets in PH include also several 
proliferative pathways. A significant number of growth 
factors are implicated in the pathogenesis of the disease 
with PDGF, FGF-2, EGF, VEGF being among them. 
These substances act on the pulmonary vascular bed as 
potent mitogens and chemoattractants, and through the 
tyrosine kinase receptor pathways activate the ras-
mitogen activated protein kinase (MAPK) cascade, 
resulting in proliferation, migration and resistance to 
apoptosis. Interruption of these hyperplastic procedures 
can be attempted by interfering in various sites of the 
biochemical pathway. Tyrosine-kinase inhibitors such as 
imatinib (Gleevec) have been attributed a favourable 
effect 36,37 and the results of a phase III trial (IMPRES) 
are awaited. Other similar molecules (sunitinib and 
sorafenib) which block PDGF, VEGF and other 
proproliferative signalling pathways are under evaluation 
for safety and tolerability in Phase I studies. 38 
Another important pathway involved in the vascular 
changes underlying PH is the Rho kinase pathway which 
mediates vasoconstriction and smooth muscle cell 
proliferation, through a complicated metabolic process 
involving 5-HT and Bone Morphogenetic Protein 
Receptor (BMPR). Rho-kinase inhibitor fasudil has been 
shown to reduce PH and pulmonary vascular resistance in 
animal models and in humans, 39,40 but it has to be 
administered by nebulization, in order to avoid systemic 
hypotension. 41  
The Bone Morphogenetic Protein Receptor system is 
involved in the pathogenesis of PAH, especially in 
inheritable forms, and it has recently emerged as a 
potential therapeutic target. PMPR2, a serine-threonine 
kinase and a member of the TGFb superfamily is mostly 
implicated, which activates the Smad protein signaling 
sequence and the MAP kinase pathways. In PAH 
mutations of BMPR2 leading to diminished expression or 
dysfunction have been reported. 42,43 Gene therapy using 
viral vectors is under investigation . 44 
Serotonin is another molecule which plays a role in 
the pathobiology of PAH. Its contribution was discovered 
when PAH secondary to anorexigen use was studied. 5-
hydroxy-tryptamine (HT; serotonin) is a potent 
vasoconstrictor and a mitogen for smooth muscle cells 
and fibroblasts. 45 At the time several agents targeting 
serotonin signaling mechanisms are under evaluation 
(serotonin receptor inhibitors terguride and re-uptake 
inhibitor escitalopram). 
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Finally, new evidence is gathered regarding well 
known and established treatment options. The Renin-
Angiotensin-Aldosterone System is activated in cases of 
PH and its inhibition with captopril is not a new idea. 46 
However, the discovery of the sybtype 2 of the 
Angiotensin Converting Enzyme (ACE2) has provided 
new insights since its role is vasoprotective and anti-
mitogenic. Stimulation of ACE2 expression either by 
lentiviral gene delivery or XNT, an ACE2 activator, can 
potentially reverse experimental PH. 47 Statins may also 
prove useful due to their antiproliferative, anti-
thrombotic, anti-inflammatory and antioxidant actions. 
Simvastatin has been efficient in decreasing pulmonary 
pressure in animal models. 48  
In conclusion, significant progress has been made in 
recent years with regard to the treatment of PAH. 
Nevertheless, efficient therapy has not been achieved yet 
and there is plenty of room for novel therapeutic 
approaches. New drugs are developing on the basis of the 
specific pathobiology of the disease and older agents find 
new indications thanks to the elucidation of the complex 
molecular and pathophysiological aspects of this 
debilitating disease.  
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IMAGES IN CARDIOLOGY  
 
Catheter Ablation of Incessant Ventricular 
Tachycardia in a Patient With Coronary Artery 
Disease 
Konstantinos P. Letsas, MD, Michael Efremidis, MD, 
Antonios Sideris, MD 
Second Department of Cardiology, Evagelismos 
General Hospital of Athens, Greece. 
 
A 67-year-old male with known coronary artery 
disease was referred to our hospital for catheter ablation 
of incessant ventricular tachycardia (VT). Transthoracic 
echocardiography revealed severe wall motion 
abnormalities of the left ventricle along with an apical 
aneurysm. Left ventricular voltage mapping showed a 
region with low voltage (<1.5 mV) at the left ventricular 
apex. Propagation mapping revealed a macro-reentry 
circuit around the apical aneurysm. Mid-diastolic 
potentials were recorded during the VT (Fig. 1, left panel, 
arrows), while entrainment mapping was excellent. The 
first radiofrequency energy application terminated the 
tachycardia. A circumferential lesion around the 
aneurysm was finally performed (Fig. 1, right panel, red 
dots). Ventricular tachycardia became non-inducible, and 
the patient is free from arrhythmic events during the last 
six months. 
